4basebio PLC Ordinary Shares (LSE:4BB) - Share price


Stock Report

4basebio PLC 4BB

Last Price
GBX630.00

Day Change
-2.50|-0.40%

As of 05/08/2022
16:35:29 BST | GBX
Minimum 15 Minutes Delay.

Last Close632.50p
Day Range612.00 - 630.00
Mkt Cap77.60Mil
52-Wk Range390.00 - 820.00
Yield %-
ISINGB00BMCLYF79
Volume118
P/E-
P/S2.30
P/CF-0.28

Share Price

Total Returns 05/08/2022

 Chg (%)  
More ...
4basebio PLC51.81 
FTSE 100 TR GBP6.17
 
Financials
201920202021
More ...
Income Statement
Turnover0.200.460.34
Operating Profit-0.42-0.62-3.19
Net Profit-0.42-0.72-3.24
Reported EPS--5.84-26.00
Balance Sheet
Current Assets0.6015.5110.64
Non Current Assets0.562.304.06
Total Assets1.1617.8114.70
Current Liabilities0.570.811.52
Total Liabilities3.052.353.01
Total Equity-1.8915.4611.70
Cash Flow
Operating Cash Flow-0.27-1.13-2.74
Net Change in Cash0.0214.85-4.72
Director Dealings
TradedActionNotifierPriceAmountValue
More ...
12/07/2022Transfer inDr. Heikki Lanckriet0.0029,0000.00
12/07/2022Transfer outDr. Heikki Lanckriet0.0029,0000.00
16/06/2022PurchaseMr. David John Roth430.005,00021,500.00
12/05/2022PurchaseDr. Heikki Lanckriet470.003,00014,100.00

Company Profile

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effective and safe delivery of these DNA-based products to patients. Its country of operation is the UK. It is engaged in the manufacturing and supply of high purity, synthetic DNA for research, therapeutic and pharmacological use.

Sector

Biotechnology

Index

FTSE AIM All-Share

Next Event 30/09/2022

Half-Yearly Results
Ratios
Comp
More ...
PER (E)0.00
Div Yld (E)0.00
PEG (E)0.00
ROCE-26.76
Op Mrgn-9.43
EPS Grwth0.00
Dividends
PreviousLatest
More ...
Record Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
Directors
More ...
Non-Executive Director, ChairmanMr. Timothy Paul McCarthy
Non-Executive DirectorDr. Joseph M. Fernandez
Non-Executive DirectorMr. Hansjorg Plaggemars
Executive Director, Chief Executive OfficerDr. Heikki Lanckriet
Executive Director, Chief Financial Officer and Company SecretaryMr. David John Roth
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2022 Morningstar. All rights reserved.